<?xml version="1.0" encoding="UTF-8"?>
<p>Immune escape mechanism is one of the reasons why tumor cells can continuously replicate and proliferate in the human body.
 <xref rid="tca13424-bib-0017" ref-type="ref">17</xref> Programmed cell death‐1/programmed cell death ligand‐1 (PD‐1/PD‐L1) inhibitors developed by selectively blocking the pathway involved in tumor cell escape have spring boarded this therapy to a new stage, which to a certain extent may maintain longer‐lasting antitumor effects.
 <xref rid="tca13424-bib-0018" ref-type="ref">18</xref>, 
 <xref rid="tca13424-bib-0019" ref-type="ref">19</xref>, 
 <xref rid="tca13424-bib-0020" ref-type="ref">20</xref> We suggest that for lung cancer patients receiving immunotherapy during the epidemic, it is not urgent to receive immunotherapy on a set date. Considering the adverse events of potential pulmonary toxicity or injury caused by immunotherapeutic drugs, immunotherapy can be suspended or postponed in patients with stable disease.
</p>
